Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Comment by JamesNeven1983on Nov 22, 2019 11:01am
61 Views
Post# 30382369

RE:🤡 🤡 CLOWN Alert: Randypeck566 is a TRAPPED SHORT 🤡 🤡

RE:🤡 🤡 CLOWN Alert: Randypeck566 is a TRAPPED SHORT 🤡 🤡 Sweet find .. never saw this one thanks for sharing...
Looking4Doubles wrote: The articles they don't want NEW INVESTORS to see !

ashpublications.org/blood/article-abstract/134/Supplement_1/5687/425473/A-Case-Report-of-the-Benefit-of-Cannabidiol

Article published in BLOOD

ALONG WITH COMPANY's comment this morning:


"The U.S. FDA has recommended that Kalytera apply for both Breakthrough Therapy and Fast Track Designations for our CBD products for prevention and treatment of acute GVHD, each of which could accelerate the approval process for these products.

Kalytera is continuing discussions with potential corporate partners for its GVHD program, as it begins planning and preparation for Phase 3 clinical testing of its CBD product in prevention of acute GVHD."



Bullboard Posts